Novartis Ag ADR (NY: NVS )
116.74
-0.42
(-0.36%)
Streaming Delayed Price
Updated: 1:50 PM EDT, Sep 10, 2024
Add to My Watchlist
All News about Novartis Ag ADR
![](https://cdn.benzinga.com/files/images/story/2024/01/08/isomorphic.png?width=1200&height=800&fit=crop)
Google's AI Spin-Off Isomorphic Labs Strikes Big Pharma Deals, Paving the Way for Future of Drug Discovery
January 08, 2024
Via Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
![](https://www.investors.com/wp-content/uploads/2023/01/Stock-AIbiotech-01-adobe.jpg)
Via Talk Markets
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop)
(NVS) - Analyzing Novartis's Short Interest
January 05, 2024
Via Benzinga
Novartis AG (NYSE: NVS) Records 52-Week High Friday Morning
January 05, 2024
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop)
Big Players' Recent Trades in NVS Options
January 04, 2024
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop)
(NVS) - Analyzing Novartis's Short Interest
December 20, 2023
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop)
(NVS) - Analyzing Novartis's Short Interest
December 01, 2023
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2024/01/04/medical-5835701_12807.jpg?width=1200&height=800&fit=crop)
![](https://investorplace.com/wp-content/uploads/2022/02/medical-tools-tech-therapeutics.png)
![](https://cdn.benzinga.com/files/images/story/2024/01/02/vygr.png?width=1200&height=800&fit=crop)
![](https://www.investors.com/wp-content/uploads/2019/01/Stock-HealthCareGurney-01-adobe.jpg)
![](https://www.marketbeat.com/logos/articles/med_20240101143211_2-gene-editing-stocks-reshaping-hereditary-disease.jpg)
![](https://cdn.benzinga.com/files/images/story/2023/12/28/cing.png?width=1200&height=800&fit=crop)
![](https://investorplace.com/wp-content/uploads/2022/10/droplet-test-tube-biotech-1600-3.jpg)
![](https://cdn.benzinga.com/files/images/story/2023/12/26/bmy.png?width=1200&height=800&fit=crop)
![](https://g.foolcdn.com/editorial/images/758794/biotech-pharma-researchers-talk-lab.jpg)
![](https://cdn.benzinga.com/files/images/story/2023/12/21/calt.png?width=1200&height=800&fit=crop)
Calliditas Therapeutics Scores Complete FDA Approval, Broader Label For Lead Kidney Disease Drug
December 21, 2023
Via Benzinga
Exposures
Product Safety
![](https://cdn.benzinga.com/files/images/story/2023/12/20/fusn.png?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2023/12/19/lnth_logo.png?width=1200&height=800&fit=crop)
![](https://investorplace.com/wp-content/uploads/2022/05/hot-stocks-1600.png)
![](https://cdn.benzinga.com/files/images/story/2023/12/15/mrk.png?width=1200&height=800&fit=crop)
FDA Approves Merck's Drug Belzutifan For Type Of Advanced Kidney Cancer In Pretreated Cancer Patients
December 15, 2023
Via Benzinga
Exposures
Product Safety
![](https://cdn.benzinga.com/files/images/story/2023/12/11/nvs_co.png?width=1200&height=800&fit=crop)
![](https://g.foolcdn.com/editorial/images/757221/scientist-peers-into-microscope-in-laboratory.jpg)
![](https://www.investors.com/wp-content/uploads/2019/10/stock-Zoetis-04-shutter.jpg)
![](https://cdn.benzinga.com/files/images/story/2023/12/06/nvs.png?width=1200&height=800&fit=crop)
Novartis' Rare Blood Disorder Therapy Scores FDA Approval
December 06, 2023
Via Benzinga
Exposures
Product Safety
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.